Frank Young Joins Bioheart as Financial Consultant

SUNRISE, Fla., Jan. 30, 2012 (GLOBE NEWSWIRE) --
News), a leader in developing stem cell therapies to treat
cardiovascular diseases, today announced that Frank Young will join
to be a financial consultant. Young will provide financial
oversight of the company's capital fundraising efforts and
cultivate relationships within the financial and health care
communities to support Bioheart's business goals.

Young previously served as chief financial officer (CFO) with
Bioheart from 2003 to 2005. He has more than 30 years'
experience launching and managing venture-backed companies in
the technology and health care industries.

"Frank's entrepreneurial spirit and successful fundraising
strategies, combined with his previous accomplishments at
Bioheart, make him an ideal fit for Bioheart," said Mike Tomas,
Bioheart's president and CEO. "Frank has a proven track record
launching, managing and financially advising numerous companies
across the healthcare industry."

Previously Young worked as CFO with CURNA,a health care company
known for its discovery of new therapeutic compounds. He
engineered the sale of the company in fewer than two years for
more than five times the invested capital. He also worked as
CFO with Mitral Solutions and Hyperion. As CFO with Bioheart,
Young assisted in raising more than $9.5 million from investors
in addition to negotiating international manufacturing
arrangements and joint ventures.

"I have always been impressed with Bioheart and its success
with stem cell research," Young said. "I look forward to
becoming an integral part of Bioheart's financial future as it
continues to develop life-saving technologies for victims of

About Bioheart

News) is committed to developing stem cell therapies to
treat congestive heart failure, lower limb ischemia, chronic
heart ischemia, acute myocardial infarctions and other medical
problems. The company focuses on the discovery and development
of therapies that will improve patients' quality of life and
reduce health care costs and hospitalizations. Bioheart's
leading product, MyoCell, is a muscle-derived cell therapy
designed to populate regions of scar tissue within a patient's
heart to improve cardiac function. For more information, visit

For more information on Bioheart, visit

Forward-Looking Statements: Except for historical matters
contained herein, statements made in this press release are
forward-looking statements. Without limiting the generality of
the foregoing, words such as "may," "will," "to," "plan,"
"expect," "believe," "anticipate," "intend," "could," "would,"
"estimate," or "continue" or the negative other variations
thereof or comparable terminology are intended to identify
forward-looking statements.

Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed
or implied by the forward-looking statements. Also,
forward-looking statements represent our management's beliefs
and assumptions only as of the date hereof. Except as required
by law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future.

The Company is subject to the risks and uncertainties described
in its filings with the Securities and Exchange Commission,
including the section entitled "Risk Factors" in its Annual
Report on Form 10-K for the year ended December 31, 2010, and
its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2011.

Go here to see the original:
Frank Young Joins Bioheart as Financial Consultant

Related Post